Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.

TiaSáng [31 January 2019]

“Tài trợ cho nghiên cứu về những “căn bệnh bị lãng quên” tăng cao kỷ lục” – “Neglected disease research funding hits record high”

Click here to read the article

DNDi welcomes the findings of the 2018 G-FINDER report

23 January 2019
Geneva, Switzerland
The annual G-FINDER report provides policy-makers, donors, researchers, and industry with a comprehensive analysis of global investment into R&D of new products to prevent, diagnose, control, or cure neglected diseases in developing countries. It gives an up-to-date analysis of how R&D investments are being allocated across 33 neglected diseases, and product types, funding trends over time, and where the potential gaps lie.

Santa Cruz Letter

15 November 2018
On November 15, 2018, members of the Chagas Clinical Research Platform and the Global Chagas Coalition, participating in the VIII Meeting of the Chagas Platform in Santa Cruz de la Sierra, Bolivia, signed this letter addressed to governments, organizations and donors requesting an intensification in the efforts to control and eliminate Chagas disease as a public health problem. In the last 10 years, there have been significant efforts in the fight against the disease. However, many challenges remain. Next 2019 marks the 110th anniversary since the discovery of the disease and constitutes an opportunity to call attention to people affected by the disease and pursue necessary actions.

DNDi welcomes Astellas to the NTD Drug Discovery Booster

The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.

Toremaga [8 December, 2016]

スーダン・ハルツーム大学のアーメド ファハル外科教授が来日 重篤な感染症「マイセトーマ(菌腫)」について講演を行う” – “Professor Ahmed Fahal, surgeon from Sudan / Khartoum University will give a lecture on the serious infectious disease: Mycetoma”

Click here to read the article